Country: Armenia
Language: English
Source: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում
lornoxicam
Takeda GmbH
M01AC05
lornoxicam
8mg
tablets film-coated
(12/2x6/) in blister
Prescription
Registered
2020-11-19
January 2015 1. NAME OF THE MEDICINAL PRODUCT Xefocam Rapid 8 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One film-coated tablet contains 8 mg lornoxicam. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet White to yellowish round biconvex film-coated tablet. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Short-term relief of acute mild to moderate pain. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION POSOLOGY For all patients the appropriate dosing regimen should be based upon individual response to treatment. Acute pain 8-16 mg lornoxicam given in doses of 8 mg. An initial dose of 16 mg followed by 8 mg 12 hours later can be given on the first treatment day. After the first treatment day the maximum recommended daily dose is 16 mg. Additional information on special populations Children and adolescents Lornoxicam is not recommended for use in children and adolescents below age 18 because of a lack of data on safety and efficacy. Elderly No special dosage modification is required for elderly patients above age 65 unless renal or hepatic function is impaired. Lornoxicam should be administered with precaution as gastrointestinal adverse effects are less well tolerated in this group (see section 4.4). _ _ Renal impairment Reduction of dose frequency of Xefocam Rapid to once daily in patients suffering from renal impairment is recommended. Hepatic impairment January 2015 Reduction of dose frequency of Xefocam Rapid to once daily in patients suffering from hepatic impairment is recommended. Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms (see section 4.4.). METHOD OF ADMINISTRATION Xefocam Rapid film-coated tablets are supplied for oral administration and should be taken with a sufficient quantity of liquid. 4.3 CONTRAINDICATIONS - hypersensitivity to lornoxicam or any of the excipients; - complete or incomplete combination of bronchial asthma, recurrent polyposis of nasal cavi Read the complete document